FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Oncodesign

Oncodesign and LNGT: research collaboration for advancing drug discovery efforts with Ipsen in Parkinson's disease

04-Jan-2013 - Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, announced that they have entered into a research ...

drug discovery Parkinson's disease

Oncodesign enters into a research collaboration and license agreement with Sanofi for the application of Oncodesign’s Nanocyclix technology to Sanofi’s kinase targets

18-Sep-2012 - Oncodesign announced that the company has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix(R) technology to several Sanofi kinase target programs. Nanocyclix(R) is a proprietary medicinal chemistry technology and research platform based on ...

kinase inhibitors Sanofi-aventis

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target

10-Jan-2012 - Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen will ...

Parkinson's disease research collaborations

Oncodesign to Develop Experimental Cancer Models for sanofi-aventis

30-Oct-2009 - Oncodesign has signed a two-year service contract with sanofi-aventis under which it is to supply and develop exclusive, experimental models in different types of cancer for sanofi-aventis. Unlike traditional models, which are derived from cultured cell lines, the models that Oncodesign is ...

cell lines Sanofi-aventis tumors +1

Oncodesign announces EUR 10 million funding for oncology biomarker program IMAkinib

12-Aug-2009 - Oncodesign announced that French innovation agency, OSEO, will provide more than 40 percent of the funding for the IMAkinib program, aimed at oncology biomarker development. The total cost of the program will be around EUR 24.7 million over eight years. Oncodesign heads the project in ...

clinical trials kinase inhibitors oncology

BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services

28-Jul-2009 - BioFocus DPI and Oncodesign announced that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In ...

BioFocus DPI biology biomarker +3